Metabolic Associated Fatty Liver Disease in Indigenous Arctic Populations: A Systematic Review Emphasizing Awareness of Minorities

Aim: Non-Alcoholic Fatty Liver Disease (NAFLD) is a leading cause of chronic liver disease affecting 25% of the World population. However, the prevalence is only sparsely investigated in circumpolar areas. We aimed to perform a systematic review of the literature to estimate the prevalence of MAFLD...

Full description

Bibliographic Details
Main Authors: Gantzel, Rasmus Hvidbjerg B., Villadsen, Gerda Elisabeth, Rex, Karsten Fleischer, Pedersen, Michael Lynge, Grønbæk, Henning
Format: Conference Object
Language:English
Published: 2022
Subjects:
Online Access:https://pure.au.dk/portal/da/publications/metabolic-associated-fatty-liver-disease-in-indigenous-arctic-populations-a-systematic-review-emphasizing-awareness-of-minorities(6af4a273-5a63-4545-b849-d388fd4fa03a).html
Description
Summary:Aim: Non-Alcoholic Fatty Liver Disease (NAFLD) is a leading cause of chronic liver disease affecting 25% of the World population. However, the prevalence is only sparsely investigated in circumpolar areas. We aimed to perform a systematic review of the literature to estimate the prevalence of MAFLD in indigenous arctic populations. Material and methods: This systematic literature review adheres to the PRISMA guidelines and the Cochrane Handbook. We included trials estimating the prevalence of NAFLD or MAFLD in the related indigenous arctic populations of Inuit, Alaska Natives, Inupiat, and Yupik residing in Greenland and Alaska, as well as Arctic Canadian territories and the Chukotka Okrug of Russia. Results: We identified 1105 unique references for screening and five studies qualified for inclusion. Four of the studies examined Alaskan Natives either with self-identification as Inupiat, Yupik, Athabascan Indian, Southeast Alaska Indian, or Aleut or in combination with other Native Americans. Only one study examined MAFLD in Greenland Inuit. The prevalence of MAFLD varied between 21% and 65%, with a considerable risk of bias from other coexisting liver diseases. One study, using the non-invasive FIB-4 score (>1.45), estimated the prevalence of liver fibrosis to be 16%, while another reported that 8% of patients with MAFLD had cirrhosis. Conclusion: In this first systematic review on the prevalence of MAFLD in arctic indigenous populations related to Inuit we showed a MAFLD prevalence of 21-65% with 16% having fibrosis. This may emphasize the need for health research of MALFD in minority populations for early detection and improving patient outcome and also taking into account demographic and cultural differences.